Enfortumab Vedotin and Pembrolizumab Show Efficacy in Bladder Cancer Treatment

Results from the interim analysis of the phase 3 EV-304 clinical trial indicate that a combination of enfortumab vedotin and pembrolizumab may serve as a promising treatment option for patients with muscle-invasive bladder cancer (MIBC). This ongoing study examines the efficacy of this combination as a platinum-free alternative for patients eligible for cisplatin-based chemotherapy.

The trial, which is open-label and randomized, focuses on the use of enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4, alongside pembrolizumab, a PD-1 inhibitor. These findings suggest significant improvements in patient outcomes when compared to the standard neoadjuvant chemotherapy.

In a statement, Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development at Astellas Pharma Inc, highlighted the positive findings: “Building on the recent US approval for cisplatin-ineligible patients living with MIBC, these positive EV-304 findings reinforce the potential of enfortumab vedotin plus pembrolizumab to improve survival outcomes for a broad population of patients living with muscle-invasive bladder cancer.”

Understanding Muscle-Invasive Bladder Cancer

MIBC affects the detrusor muscle of the bladder, where it is more likely to spread to other areas of the body. This type of cancer accounts for nearly 30% of all bladder cancer cases and ranks as the third most common cancer among men in the United States, predominantly impacting individuals aged 75 to 84 years. Current treatment options include bladder removal, chemotherapy, and radiation therapies, among others.

Despite these treatments, nearly half of MIBC patients progress to metastatic disease within three years of diagnosis, according to Christopher Hoimes, DO, director of the bladder cancer program at Duke Cancer Institute and an EV-304 principal investigator. He stated, “Despite available treatment options, nearly half of patients with muscle-invasive bladder cancer progress to metastatic disease within three years of diagnosis.”

Mechanism and Study Outcomes

Enfortumab vedotin is a first-in-class antibody-drug conjugate that targets Nectin-4, a protein commonly found on the surface of bladder cancer cells. The drug delivers monomethyl auristatin E (MMAE) directly into the cancer cells, inducing cell cycle arrest and apoptosis.

The EV-304 trial compared the combination of enfortumab vedotin and pembrolizumab with standard neoadjuvant chemotherapy, including gemcitabine and cisplatin, among cisplatin-eligible patients. The study successfully met its primary endpoints, demonstrating clinically meaningful and statistically significant improvements in event-free survival and overall survival.

These positive results align with findings from the earlier EV-303 trial, where the same combination significantly outperformed surgery alone in terms of event-free survival and overall survival. Collectively, these studies suggest the potential for establishing a new, platinum-free standard of care in treating earlier stages of bladder cancer.

Dr. Chatterjee-Kishore expressed optimism about these findings: “The EV-304 results represent a key milestone in the new era of urothelial cancer treatment. Together, the EV-303 and EV-304 results show that perioperative enfortumab vedotin plus pembrolizumab can positively impact the treatment journey for patients with MIBC, offering significant survival gains across cisplatin-ineligible and cisplatin-eligible patients.”

As the clinical landscape evolves, the combination of enfortumab vedotin and pembrolizumab appears to offer a strong, evidence-based alternative for patients battling muscle-invasive bladder cancer, paving the way for enhanced treatment options and improved patient outcomes.